Adrenoleukodystrophy (ALD) Market Insights, Epidemiology and Market Forecast - 2027 - ResearchAndMarkets.com

DUBLIN--()--The "Adrenoleukodystrophy (ALD) Market Insights, Epidemiology and Market Forecast - 2027" drug pipelines has been added to ResearchAndMarkets.com's offering.

The market of Adrenoleukodystrophy in 7MM was found to be USD 135.9 million in 2016, and is expected to increase from 2016-2027.

This report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Adrenoleukodystrophy (ALD) in the United States, EU5, and Japan.

One segment of the Adrenoleukodystrophy report encloses the detailed analysis of marketed drugs and late stage pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

There is no approved therapy for the treatment of ALD in the market. The current therapeutic market is being ruled solely by transplantation [for severe cases of cerebral Adrenoleukodystrophy (CALD)] and steroids [in case of Adrenal insufficiency] in absence of any approved pharmacological therapy for the treatment of ALD in the United States. Detailed chapter for upcoming therapies Lenti-D, MIN-102, OP-101, MD1003 and NV1205 have been covered in the report.

The Adrenoleukodystrophy market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

Key Topics Covered:

1. Key Insights

2. Adrenoleukodystrophy Market Overview at a Glance

3. Disease Background and Overview: Adrenoleukodystrophy (ALD)

4. Epidemiology and Patient Population

5. 7MM Prevalent Population of Adrenoleukodystophy (ALD)

6. Country Wise-Epidemiology of Adrenoleukodystrophy (ALD)

7. Current Treatment and Medical Practices

8. Unmet Needs

9. Emerging Therapies

10. Phase II/III Drugs

11. Phase I/II Drugs

12. Adrenoleukodystrophy (ALD): Market Analysis

13. Adrenoleukodystrophy (ALD): Total Market Size in 7MM

14. Market Size of Adrenoleukodystrophy (ALD) by Country

15. Japan: Market Analysis

16. Market Drivers

17. Market Barriers

18. Appendix

19. Report Methodology

20. Capabilities

21. Disclaimer

For more information about this drug pipelines report visit https://www.researchandmarkets.com/researc/zr2g/adrenoleukodystrop?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Central Nervous System Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Central Nervous System Drugs